Pacira Biosciences Inc
F:82P
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pacira Biosciences Inc
F:82P
|
US |
|
Oil Country Tubular Ltd
NSE:OILCOUNTUB
|
IN |
|
Chongqing Sansheng Industrial Co Ltd
SZSE:002742
|
CN |
|
Pacific Arc Resources Ltd
XTSX:PAV.H
|
CA |
|
Porto Seguro SA
BOVESPA:PSSA3
|
BR |
|
B
|
Blue Sky Energy Inc
XTSX:BSI.H
|
CA |
|
adesso SE
OTC:ADSGF
|
DE |
|
T
|
Tomony Holdings Inc
TSE:8600
|
JP |
|
J
|
James Bay Resources Ltd
CNSX:JBR
|
CA |
|
Antarctica Ltd
NSE:ANTGRAPHIC
|
IN |
Pacira Biosciences Inc
Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Revenue Growth: Pacira reported full-year 2025 revenue of $726 million, with EXPAREL sales increasing to $155.8 million in Q4, up from $147.7 million the previous year.
Gross Margins: The company achieved its highest gross margins in history, with Q4 consolidated gross margin at 80%, up from 79% last year.
EXPAREL Coverage: EXPAREL ended 2025 with 102 million lives covered outside the surgical bundle, exceeding internal goals and marking a significant shift in payer policy.
Guidance: 2026 revenue guidance is set at $745–770 million, with EXPAREL sales expected between $600–620 million. Non-GAAP gross margins are guided to 77–79%.
Strategic Partnerships: Notable partnerships with LG Chem (for Asia-Pacific markets) and J&J MedTech (tripling U.S. reach for ZILRETTA) were highlighted as key growth drivers.
Pipeline Progress: The pipeline is entering a data-rich phase, with key clinical milestones expected in 2026, including Phase II results for PCRX-201 and PCRX-2002.
Share Repurchases: $150 million in stock repurchases were completed in 2025, reducing shares outstanding to 41 million.
